FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
2019 ASCO Annual Meeting Proceedings Immuno-Oncology Abstracts | Journal of Clinical Oncology
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine - Li - 2020 - Journal of the Chinese Chemical Society - Wiley Online Library
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
PDF) New clinical trial designs in the era of Precision Medicine
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Life | Free Full-Text | Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Frontiers | Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Cancers | Free Full-Text | Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
